Business
PetLife Pharmaceuticals Retains Invicto Group as their Investor Relations Firm
PetLife Pharmaceuticals Retains Invicto Group as their Investor Relations Firm.
About this update from Petlife Pharmaceuticals Inc
[{"type":"text","content":"\n\n HANCOOK, Md., July 19, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTCQB:PTLF), a developer of new generation of high potency veterinary cancer medications and nutraceuticals for pets, today announces it has retained Invicto Group, a leading investors relations and strategic advisory firm.\n Dr. Ralph T. Salvagno, CEO of Petlife Pharmaceuticals noted, “Petlife is poised to change the paradigm of treatment in veterinary oncology. It is reported that over 50% of dogs and cats living past the age of 10 develop cancer meaning that approximately 13 million families yearly have to face this diagnosis in their beloved companion animals. Our all natural Escozine for Pets™ has a strong scientific basis for the treatment of cancer and offers an alternative to standard chemotherapy, surgery and other invasive treatment that are often as toxic as the cancer itself. Petlife’s mission is to provide an affordable solution that also avoids the unfortunate and often deadly side effects of traditional treatment. We hope to soon announce our Investigational New Drug Application seeking FDA approval for our technology and will also work to develop a daily nutraceutical preventive formulation.  We are excited to be working with Invicto Group to assist in our efforts to bring this breakthrough drug to market.” “After completing our due diligence of the company and its products we look forward to introducing PetLife Pharmaceuticals to the financial and investment community. In addition, we will look to reach out to the over 92 million pet owners in the U.S. and millions more around the world,” said Invicto Group. About PetLife Pharmaceuticals, Inc. PetLife Pharmaceuticals (OTCQB:PTLF) (www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012. PetLife has developed and is launching a new generation of high potency veterinary cancer medications and nutraceuticals for companion pets -- Escozine for Pets™. It is based on the same patented 'Escozine for Humans' formula that has been sold by affiliated companies worldwide in 40 countries.  Escozine for Pets™ uses a patented polarization technology that potentiates the main ingredients to dramatically increase their effectiveness. PetLife's mission is to bring its new, scientifically ...